Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Basis: International Financial Reporting Standards (IFRS)
Business Overview: Grifols is a vertically integrated global producer of plasma derivatives, diagnostics, and hospital products. The company operates four divisions: Bioscience (77.1% of revenue), Diagnostic (17.6%), Hospital (2.4%), and Raw Materials and Others (2.9%). Key products include IVIG, A1PI, Factor VIII, and albumin. The company operates 159 plasma collection centers in the U.S. and manufacturing facilities in the U.S. and Spain.
Key Financial Metrics (Year Ended Dec 31, 2015)
| Metric | 2015 (€ millions) | 2014 (€ millions) | Change |
|---|---|---|---|
| Net Revenue | 3,934.6 | 3,355.4 | +17.3% |
| Gross Profit | 1,931.0 | 1,699.2 | +13.6% |
| Gross Margin | 49.1% | 50.6% | -150 bps |
| Operating Result (EBIT) | 970.4 | 857.7 | +13.1% |
| Net Profit (Parent) | 532.1 | 470.3 | +13.1% |
| EPS (Basic) | €0.78 | €0.69 | +13.0% |
| Operating Cash Flow | 742.8 | 978.9 | -24.1% |
| Cash & Equivalents | 1,142.5 | 1,079.1 | +5.9% |
| Total Debt (Approx.) | ~€5.3 billion | ~€4.8 billion | Increased |
Note: Revenue growth of 17.3% included a favorable foreign exchange impact of approximately €493.8 million. Constant currency revenue growth was 2.5%.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Bioscience division (+20.6% reported, +4.8% constant currency) due to increased sales volume of IVIG and A1PI. The Diagnostic division grew 11.5% reported but declined 0.9% at constant currency.
- Margin Compression: Gross margin decreased from 50.6% to 49.1%. Management attributed this to competitive pricing in the U.S. IVIG market, the simultaneous operation of two fractionation plants at the Clayton facility during a transition, and higher plasma costs due to new center investments.
- Working Capital: Significant improvement in receivables collection, with days sales outstanding dropping from 55 days in 2014 to 34 days in 2015, generating a €170 million cash inflow. Inventory levels increased by €120.6 million to support higher activity.
- Debt Structure: The company incurred a new €100 million term loan from the European Investment Bank in October 2015 to fund R&D. Total indebtedness stood at approximately $5.3 billion (€4.8 billion) as of year-end.
Guidance, Outlook, and Risks
Outlook and Capital Plan: Grifols expects to undertake an investment plan involving approximately $360 million in cumulative industrial capital expenditures from 2016 through 2021 to expand manufacturing capacity. The company plans to increase its plasma collection network to 225 centers by 2021. R&D spending is expected to remain in the range of 5% to 6% of net revenues.
Key Risks and Contingencies:
- Plasma Supply: Reliance on U.S. source plasma; supply constraints or increased donor costs could impact margins and growth.
- Regulatory & Compliance: Extensive FDA and EMA oversight; risks related to cGMP compliance, product recalls, and potential contamination.
- Reimbursement & Pricing: Pressure from U.S. healthcare reform (Medicare/Medicaid rebates, 340B program) and price controls in European markets.
- Debt Service: Significant indebtedness ($5.3 billion) creates vulnerability to economic downturns and interest rate fluctuations (81.1% of senior debt is variable rate).
- Competition: Increased competition in IVIG and A1PI markets, including potential biosimilar competition in the future.
Investor Verification Checklist
- Constant Currency Performance: Verify the underlying organic growth rate (2.5%) versus the reported growth (17.3%) to assess operational momentum independent of FX fluctuations.
- Plasma Collection Capacity: Confirm progress on opening new plasma centers and the cost per liter of plasma to validate margin recovery strategies.
- Clayton Facility Transition: Monitor the completion of the transition to the new Clayton fractionation plant to ensure the temporary margin drag resolves as planned.
- Debt Covenants: Review leverage ratios and interest coverage to ensure compliance with Credit Facility covenants, particularly given the high debt load and variable interest rates.
- Receivables Quality: Assess the aging of receivables in Southern Europe (Spain, Italy, Portugal, Greece) where payment delays from public entities remain a risk.